AFT Pharmaceuticals Wins Appeal in Pascomer Profit-Sharing Dispute

An update from AFT Pharmaceuticals Ltd. ( (AU:AFP) ) is now available.

AFT Pharmaceuticals has secured a favourable Court of Appeal judgment in New Zealand, which dismissed a claim by PBL Solutions for a share of any profits from the use of AFT’s topical skin medicine Pascomer in treating Port Wine Stains, a non-orphan indication. The ruling confirms that profit-sharing with PBL remains limited to orphan drug applications of Pascomer, with costs of the appeal shared, and AFT does not expect any material impact on its FY 2026 earnings guidance, reinforcing certainty over future economics from a potentially much larger non-orphan market.

The dispute centred on whether PBL, a 35% shareholder in AFT Orphan Pharmaceuticals, was entitled to share in profits from broader, non-orphan uses of Pascomer beyond rare-disease indications. By upholding the earlier High Court decision and keeping non-orphan profits outside the shared pool, the judgment supports AFT’s control over the more commercially significant Port Wine Stain opportunity, providing clarity for investors on the company’s rights to future returns from this asset.

More about AFT Pharmaceuticals Ltd.

AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company that develops, markets and distributes a broad portfolio of proprietary and in-licensed medicines across over-the-counter, prescription and hospital channels. Its products, including patented, branded and generic drugs, are sold in core markets such as Australia, New Zealand, parts of Asia, North America and Europe, with out-licensing agreements extending its reach to more than 125 countries.

Average Trading Volume: 1,508

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$307.7M

For a thorough assessment of AFP stock, go to TipRanks’ Stock Analysis page.